Clinical Impact of C-myc Oncogenic Diversity on Solid and Lymphoid Malignancies

Overview

Journal Maedica (Bucur)

Specialty General Medicine

Date 2024 Aug 27

PMID 39188831

Authors

Sotirios Papouliakos

Aristeidis Chrysovergis

Vasileios Papanikolaou

Despoina Spyropoulou

Georgios Papanastasiou

Asimakis D Asimakopoulos

Sofianiki Mastronikoli

Panagiotis Stathopoulos

Dimitrios Roukas

Maria Adamopoulou

Evangelos Tsiambas

Dimitrios Peschos

Pavlos Pantos

Vasileios Ragos

Nicholas Mastronikolis

Efthymios Kyrodimos

Affiliations

Soon will be listed here.

Abstract

Introduction: Onset and progression of malignant tumors is a multistep process including a variety of gross chromosomal and specific genes' deregulation. Among oncogenes that are frequently altered in solid and also in hematological malignancies, the C-myc (gene locus: 8q24.21) plays a pivotal role. C-myc is a proto-oncogene encoding for a nuclear phosphoprotein implicated in cell cycle progression, apoptosis and cellular differentiation and transformation.

Objective: The purpose of the current molecular review was to explore the differences of C-myc oncogenic activity in solid and lymphoid malignancies that modify its clinical impact on them.

Material And Method: A systematic review of the literature in the international database PubMed was carried out. The year 2010 was set as a prominent time limit for the publication date of articles in the majority of them, whereas specific references of great importance and historical value in the field of C-myc gene discovery and analysis were also included. The following keywords were used: C-myc, oncogene, signaling pathway, malignancies, carcinoma, lymphoma. A pool of 43 important articles were selected for the present study at the basis of combining molecular knowledge with new targeted therapeutic strategies.

Results: C-myc oncogene demonstrates two different mechanisms of deregulation: amplification, mutation and translocation patterns. These particular aspects of gene alteration are unique for solid and non-solid (hematological) malignancies, respectively.

Conclusions: C-myc is characterized by diversity regarding its deregulation mechanisms in malignancies derived from different tissues. C-myc translocation is sporadically combined with amplification ("complicon" formation) or mutations creating exotic genetic signatures. This "bi-phasic" C-myc deregulation model in the corresponding malignant tumor categories clinically affects the corresponding patients, also modifying the targeted therapeutic strategies on them.

Citing Articles

Exosomal ncRNAs in reproductive cancers†.

Kowalczyk A, Wrzecinska M, Galeska E, Czerniawska-Piatkowska E, Camina M, Araujo J Biol Reprod. 2024; 112(2):225-244.

PMID: 39561105 PMC: 11833474. DOI: 10.1093/biolre/ioae170.

References

Grandori C, Cowley S, James L, Eisenman R . The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000; 16:653-99. DOI: 10.1146/annurev.cellbio.16.1.653. View

Liu C, Ren Q, Deng J, Wang S, Ren L . c-MYC/METTL3/LINC01006 positive feedback loop promotes migration, invasion and proliferation of non-small cell lung cancer. Biomed J. 2023; 47(4):100664. PMC: 11340496. DOI: 10.1016/j.bj.2023.100664. View

Chen G, Chen S, Liu S, Hsieh C, Lee S, Huang S . Stabilization of the c-Myc Protein via the Modulation of Threonine 58 and Serine 62 Phosphorylation by the Disulfiram/Copper Complex in Oral Cancer Cells. Int J Mol Sci. 2022; 23(16). PMC: 9409128. DOI: 10.3390/ijms23169137. View

Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel M . Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007; 21(3):515-23. DOI: 10.1038/sj.leu.2404529. View

Baeissa H, Benstead-Hume G, Richardson C, Pearl F . Identification and analysis of mutational hotspots in oncogenes and tumour suppressors. Oncotarget. 2017; 8(13):21290-21304. PMC: 5400584. DOI: 10.18632/oncotarget.15514. View

Hong Z, Xu C, Zheng S, Wang X, Tao Y, Tan Y . Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression. Cell Death Discov. 2023; 9(1):392. PMC: 10597990. DOI: 10.1038/s41420-023-01682-w. View

Cai H, Lv M, Wang T . PANoptosis in cancer, the triangle of cell death. Cancer Med. 2023; 12(24):22206-22223. PMC: 10757109. DOI: 10.1002/cam4.6803. View

Kim S, Armand J, Safonov A, Zhang M, Soni R, Schwartz G . Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Rep. 2023; 42(11):113198. PMC: 10757862. DOI: 10.1016/j.celrep.2023.113198. View

Xie F, Meves A, Lehman J . The genomic and proteomic landscape in oral lichen planus versus oral squamous cell carcinoma: a scoping review. Int J Dermatol. 2022; 61(10):1227-1236. DOI: 10.1111/ijd.16273. View

10.

Schmitz R, Young R, Ceribelli M, Jhavar S, Xiao W, Zhang M . Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490(7418):116-20. PMC: 3609867. DOI: 10.1038/nature11378. View

11.

Luscher B, Larsson L . The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene. 1999; 18(19):2955-66. DOI: 10.1038/sj.onc.1202750. View

12.

Bagci O, Kurtgoz S . Amplification of Cellular Oncogenes in Solid Tumors. N Am J Med Sci. 2015; 7(8):341-6. PMC: 4561439. DOI: 10.4103/1947-2714.163641. View

13.

Zenebe B, Nigussie H, Belay G, Seboka N . A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes. Hematology. 2023; 28(1):2284038. DOI: 10.1080/16078454.2023.2284038. View

14.

Sall F, Shmakova A, Karpukhina A, Tsfasman T, Lomov N, Canoy R . Epstein-Barr virus reactivation induces MYC-IGH spatial proximity and t(8;14) in B cells. J Med Virol. 2023; 95(3):e28633. DOI: 10.1002/jmv.28633. View

15.

Kreuzaler P, Inglese P, Ghanate A, Gjelaj E, Wu V, Panina Y . Vitamin B supports MYC oncogenic metabolism and tumor progression in breast cancer. Nat Metab. 2023; 5(11):1870-1886. PMC: 10663155. DOI: 10.1038/s42255-023-00915-7. View

16.

Ott G, Rosenwald A, Campo E . Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology Am Soc Hematol Educ Program. 2013; 2013:575-83. DOI: 10.1182/asheducation-2013.1.575. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Meehan K, Vella L . The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin Lab Sci. 2015; 53(2):121-31. DOI: 10.3109/10408363.2015.1092496. View

19.

Moon H, Park H, Ro S . c-Myc-driven Hepatocarcinogenesis. Anticancer Res. 2021; 41(10):4937-4946. DOI: 10.21873/anticanres.15307. View

20.

Colby W, Chen E, Smith D, Levinson A . Identification and nucleotide sequence of a human locus homologous to the v-myc oncogene of avian myelocytomatosis virus MC29. Nature. 1983; 301(5902):722-5. DOI: 10.1038/301722a0. View